Ads
related to: genmab biotech- Careers
Join our Mission to Improve
the Lives of Patients.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Sign Up
Sign Up for Updates, News
and Much More.
- About Us
Discover the Unique Approach
That Makes Genmab Different.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Careers
Search results
Results From The WOW.Com Content Network
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. [7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, the Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, and Genmab K.K. in Tokyo, Japan.
Shares in Danish biotech firm Genmab <GMAB.CO> fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson <JNJ.N> over royalty payments for ...
About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms ...
Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. [9] Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma.
They also said the results of the clinical trial would be submitted for presentation at an upcoming medical congress and discussed with regulatory authorities. "Demonstrating a survival benefit ...
Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999. [10] The company was acquired by Bristol Myers Squibb in 2009 for $2.4 billion, which included $300 million in debt, making the payment to Medarex $2.1 billion. [11] [12]
The stock of Genmab A/S (NAS:GMAB, 30-year Financials) is estimated to be significantly undervalued, according to GuruFocus Value calculation.
Ofatumumab was jointly developed by Danish biotech Genmab and GlaxoSmithKline GSK plc who entered into an agreement to co-develop and commercialize ofatumumab in 2006. [27] It was approved as Arzerra for the treatment of chronic lymphocytic leukemia in the United States in October 2009. [28] [29]
Ad
related to: genmab biotech